These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19081527

  • 1. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
    Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN, Reach Study Group.
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1378-84. PubMed ID: 19081527
    [Abstract] [Full Text] [Related]

  • 2. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 3. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
    Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E.
    Aliment Pharmacol Ther; 2004 Sep 15; 20(6):607-14. PubMed ID: 15352908
    [Abstract] [Full Text] [Related]

  • 4. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 15; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 5. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS.
    Am J Gastroenterol; 2003 Apr 15; 98(4):833-8. PubMed ID: 12738464
    [Abstract] [Full Text] [Related]

  • 6. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar 10; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 8. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, Szymanska S, Woynarowski M, Ryzko J.
    Eur J Gastroenterol Hepatol; 2012 May 10; 24(5):495-500. PubMed ID: 22387887
    [Abstract] [Full Text] [Related]

  • 9. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A.
    Rheumatology (Oxford); 2006 Jun 10; 45(6):761-4. PubMed ID: 16436492
    [Abstract] [Full Text] [Related]

  • 10. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS, Markowitz J, Wyllie R.
    J Pediatr; 2000 Aug 10; 137(2):192-6. PubMed ID: 10931411
    [Abstract] [Full Text] [Related]

  • 11. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.
    Gastrointest Endosc; 2006 Mar 10; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [Abstract] [Full Text] [Related]

  • 12. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
    Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E.
    Aliment Pharmacol Ther; 2004 Oct 15; 20(8):851-7. PubMed ID: 15479356
    [Abstract] [Full Text] [Related]

  • 13. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 15; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 14. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
    de Ridder L, Escher JC, Taminiau JA.
    Ned Tijdschr Geneeskd; 2002 Oct 05; 146(40):1879-83. PubMed ID: 12395595
    [Abstract] [Full Text] [Related]

  • 15. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A, Jackson B, Pfeiffer D, Ingham K, Horton MA, Price JS.
    Res Vet Sci; 2004 Aug 05; 77(1):29-39. PubMed ID: 15120950
    [Abstract] [Full Text] [Related]

  • 16. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF.
    Scand J Gastroenterol; 2007 Apr 05; 42(4):464-70. PubMed ID: 17454856
    [Abstract] [Full Text] [Related]

  • 17. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
    Bernstein M, Irwin S, Greenberg GR.
    Am J Gastroenterol; 2005 Sep 05; 100(9):2031-5. PubMed ID: 16128948
    [Abstract] [Full Text] [Related]

  • 18. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.
    Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR.
    J Clin Gastroenterol; 2006 Jan 05; 40(1):55-63. PubMed ID: 16340635
    [Abstract] [Full Text] [Related]

  • 19. A two-year longitudinal study of persistent lean tissue deficits in children with Crohn's disease.
    Sylvester FA, Leopold S, Lincoln M, Hyams JS, Griffiths AM, Lerer T.
    Clin Gastroenterol Hepatol; 2009 Apr 05; 7(4):452-5. PubMed ID: 19249399
    [Abstract] [Full Text] [Related]

  • 20. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D, Kökönyei G, Arató A, Dezsőfi A, Molnár K, Müller KE, Lakatos PL, Papp M, Lovász BD, Golovics PA, Cseh A, Veres G.
    J Crohns Colitis; 2014 Aug 05; 8(8):747-55. PubMed ID: 24434181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.